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Abstract
Introduction: We aimed to determine whether levels of thyroglobulin measured in blood from the inferior-superior thyroid veins and the 
peripheral antecubital vein could predict the presence of thyroid carcinoma in patients undergoing surgery for thyroid diseases.
Material and methods: Sixty-one patients were prospectively enrolled in the study. Levels of thyroglobulin were analysed. Sensitivity, 
specificity, positive predictive values (PPV) and negative predictive values (NPV) of these markers were investigated.
Results: Twenty-six out of 61 patients (42.6%) with malignancy were diagnosed. The levels of thyroglobulin in the inferior-superior thy-
roid veins were higher than those in the peripheral antecubital vein (p = 0.001). The levels of thyroglobulin in the blood taken from the 
antecubital vein and the inferior-superior thyroid veins did not differ between benign and malignant thyroid disorders. For thyroglobulin, 
sensitivity was 33.3%, specificity 60.6%, PPV 27.8%, and NPV 66.7% respectively.
Conclusion: Thyroglobulin levels in the antecubital vein compared to the inferior-superior thyroid veins were not significant either in 
benign or malignant disorders. (Pol J Endocrinol 2012; 63 (3): 202–205)
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Streszczenie
Wstęp: Celem badania było ustalenie, czy oznaczenie stężeń tyreoglobuliny we krwi pobranej z żył tarczowych górnych i dolnych oraz 
z żyły przedłokciowej ma wartość prognostyczną w wykrywaniu nowotworów tarczycy u chorych poddawanych zabiegom chirurgicz-
nym z powodu chorób tarczycy.
Materiał i metody: Do tego prospektywnego badania włączono 61 chorych. Analizowano wartości stężeń tyreoglobuliny. Badano czułość, 
swoistość oraz wartość prognostyczną dodatnią (PPV) i ujemną (NPV) tych wskaźników.
Wyniki: U 26 spośród 61 chorych (42,6%) rozpoznano chorobę nowotworową. Stężenia tyreoglobuliny w żyłach tarczowych dolnych 
i górnych były wyższe niż stężenia mierzone we krwi pobranej z żyły przedłokciowej (p = 0,001). Stężenia tyreoglobuliny w próbkach 
krwi pobranych z żyły przedłokciowej i żył tarczowych nie różniły się istotnie między osobami z łagodnymi i złośliwymi guzami tarczycy. 
Oznaczenie tyreoglobuliny cechowało się czułością wynoszącą 33,3%, swoistością równą 60,6%, PPV — 27,8% i NPV — 66,7%.
Wnioski: Porównanie stężeń tyreoglobuliny w żyle przedłokciowej i w żyłach tarczowych górnych i dolnych nie miało istotnego znaczenia 
diagnostycznego w wykrywaniu zarówno zmian łagodnych, jak i złośliwych. (Endokrynol Pol 2012; 63 (3): 202–205)
Słowa kluczowe: tyreoglobulina, próbki krwi z żył tarczowych, nowotwór tarczycy
Introduction
Thyroid cancers represent the commonest malignancy 
of the endocrine system, and the second commonest 
malignancy in the head and neck region (excluding skin 
cancers) [1]. The initial evaluation of the thyroid nodule 
continues to rely chiefly on fine needle aspiration (FNA) 
and ultrasound imaging. Despite the improvements in 
imaging methods and the wide usage of FNA, there is 
also a group of patients who cannot be diagnosed as 
differentiated thyroid carcinoma preoperatively [2]. 
Two of the advances in optimising operative strategy 
in thyroid disorders are intraoperative frozen section 
analysis and intraoperative touch imprint cytology [3]. 
They might improve outcomes in patients with suspi-
cious nodular disorders of the thyroid gland. 
Recent clinical guidelines have attempted to settle 
various controversies, but many inherent errors of clini-
cal testing result in delayed diagnosis and unnecessary 
surgery. A better solution may ultimately involve the 
use of molecular markers of thyroid carcinogenesis, 
but further research is still needed regarding the basic 
biology of thyroid cancer [4]. A very well known marker 
for medullary thyroid carcinoma, calcitonin, is the 
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most reliable marker in the course of the disease. We 
hypothesised that the concentrations of thyroglobulin 
for thyroid carcinoma would be higher in blood taken 
from the thyroid vein, relative to their concentrations 
in systemic blood. 
The purpose of this study was therefore to test the 
hypothesis as to whether blood levels of the markers dif-
fer between the inferior thyroid vein and the peripheral 
circulation, and also to test whether these markers are 
useful in predicting the diagnosis made via microscopic 
exams of tissue specimens. 
Material and methods
Sixty-one consecutive patients with an FNA diagnosis 
of suspicious for malignancy or malignant nodular 
goitre were prospectively enrolled in the study. The 
study was approved by the local ethics committee and 
written informed consent was obtained from each pa-
tient. Our research complied with the principles of the 
Helsinki Declaration. 
Of the 61 patients, 48 were female (78.7%) and 13 
were male (21.3%). Overall mean age was 47 years 
(range 23–78 years). Patients with thyroid cancers with 
distant metastases or a history of previous radiation 
exposure were excluded. All patients were preopera-
tively evaluated by physical examination, monitoring 
of serum thyroglobulin and serum thyrotropin, neck 
ultrasonography, and chest radiography. Thyroid scans 
were performed in all patients. Ultrasound-guided FNA 
was successfully performed using a 22-G needle prior 
to surgery. Smears of the FNA samples were stained by 
May-Grünwald-Giemsa stain and evaluated immedia-
tely by the cytologist. Patients with suspicious nodules 
were re-evaluated with intraoperative frozen section. 
Final diagnoses were confirmed postoperatively with 
permanent histopathological sections. Levels of serum 
thyroglobulin were measured in 10 ml of blood taken 
from the antecubital vein preoperatively, and in 10 ml 
of blood taken from the inferior-superior thyroid vein 
intraoperatively at the beginning of surgery. 
The samples were centrifuged at 3,500 rpm for 
5 minutes in order to separate the plasma. After 
separation, all samples were frozen at –30° and levels 
of thyroglobulin were measured with a Liaison kit 
(Byk-Songtec Diagnostica, Liaison thyroglobulin, 2001 
USA) by immunometric assay. Normal levels for thyro-
globulin were 1.5–4 ng/mL respectively. All malignant 
patients were separated into two groups. The separation 
was performed in two different ways to find out the 
positive predictability of independent variables (levels 
of thyroglobulin) for subjects due to postoperative 
histopathologic diagnosis. Re-arranged end results of 
the patients and their groups: prevalence of malignant 
cases; correlation of the levels of samples from benign 
cases (n = 35) with those of malignant patients (n = 26) 
according to postoperative histological examination. 
Sensitivity, specificity and predictivity were assessed 
for thyroglobulin as follows: sensitivity (definition of the 
thyroid cancers detected with high marker levels) was 
defined as true positive / [true positive + false nega-
tive]; specificity (definition of benign thyroid diseases 
detected with normal levels of markers) was defined as 
true negative / [true negative + false positive]; positive 
predictive value (PPV) (probability of diagnosing the 
disease if the FNA is positive) and negative predictive 
value (NPV) (probability of diagnosing normal subjects 
if the FNA is negative) were calculated as follows: 
 — PPV: (Prevalence) × (Sensitivity) / (Preva-
lence) × (Sensitivity) + [(1-Prevalance) × (1-Speci-
ficity)] 
 — NPV:  [ ( 1 -Preva lance )  ×  (Spec i f i c i ty )  / 
/ [(1-Prevalance) × (Specificity)] + [(Prevalence) × 
× (1-Sensitivity)]
 — Numeric variables between the groups were ana-
lysed using Mann-Whitney U test. The significance 
level was taken at p below 0.05.
Results
Preoperatively, eight patients (13.1%) were diagnosed 
with thyroid malignancy by FNA. According to the 
postoperative pathology reports, an additional 18 pa-
tients were diagnosed with malignancy. Thus in total, 
26 patients (42.6%) with malignancy were diagnosed. 
All cases underwent surgery after achieving a euthy-
roid state. All nodules presented with a solid or mixed 
(solid-cystic) pattern. Mean nodule size was 21.1 mm 
(min 1.2 mm, max 9.5 cm). Mean size of the nodule 
was 29.4 mm in benign, and 21.3 mm in malignant, 
subjects. There were 42 cases with multinodular goitre, 
and 12 cases with single solitary nodule. We detected 
seven malignancies among 12 cases (58.33%) with single 
solitary nodule and 19 malignancies among 42 cases 
(45.23%) with multinodular goitre. This difference was 
not significant (p = 0.27). The difference in mean size of 
the nodules between the two groups was not significant 
(p = 0.11). In thyroid scans, there were only three cases 
of hot nodule.
Less than total thyroidectomy was performed in 
32 patients (52.4%) and total thyroidectomy in 29 patients 
(47.6%). Papillary thyroid carcinoma was detected in 20 
patients (32.8%), and follicular thyroid carcinoma in six 
patients (9.8%). Six of 20 cases with papillary thyroid 
cancer had occult carcinoma. None of the patients had 
enlarged cervical lymph nodes.
Mean values of thyroglobulin in blood taken from 
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their ratios relative to postoperative diagnosis according 
to permanent section, are shown in Table I.
According to postoperative diagnoses, the levels of 
thyroglobulin differed significantly between patients 
with malignancy and those with benign disease. In 
terms of the veins from which the samples were drawn, 
thyroglobulin levels were much higher in inferior-su-
perior thyroid veins, and this difference was significant 
(p = 0.001) For thyroglobulin marker, the ratio of levels 
in peripheral antecubital vein blood to levels in inferior 
thyroid vein blood was calculated. The ratio of the lev-
els of markers in antecubital vein to inferior-superior 
thyroid veins were not significant either in benign or 
malignant disorders. 
Sensitivity, specificity, PPV and NPV were calcula-
ted. For thyroglobulin, sensitivity was 33.3%, specificity 
60.6%, PPV 27.8%, and NPV 66.7%, respectively.
Thyroglobulin levels have provided additional 
information on the course of the disease beside that 
provided by FNA. Also, in cases with occult carcinoma, 
levels of thyroglobulin were within normal limits both 
in the antecubital vein and the inferior-superior thy-
roid veins. Furthermore, we detected elevated levels 
of thyroglobulin in cases with benign disorders that in 
turn prevented their use as a guide to avoid operative 
interventions.
Discussion
Surgical treatment is still the treatment of choice for 
most thyroid diseases, especially for malignant dis-
orders. Often, surgery is carried out in the presence 
of a suspicious nodule [5]. Preoperative diagnosis of 
thyroid malignancies predicts the limits of the surgical 
procedure. Furthermore, early detection of asympto-
matic malignancy leads to better prognosis and out-
come. Cost-effective screening methods used in other 
solid cancers like PSA, NSE, and b-HCG are still lacking 
in the early diagnosis of thyroid malignancies [6]. In 
experienced hands, diagnostic accuracy of about 90% 
is obtained by FNA [7]. In general, 20–30% of patients 
are referred for surgery on the basis of the FNA features 
[8]. Approximately one third (17% to 51%) of these cases 
have a thyroid malignancy. False-negative rates range 
from 1% to more than 11% [9]. The sensitivity is about 
95%, and the specificity is 95% [10]. In our series, we 
detected lower rates of sensitivity and specificity in 
cases investigated for selective venous sampling with 
respect to thyroglobulin levels, thereby preventing their 
usage as a diagnostic or screening tool. However, like 
FNA, detection of TSH mRNA yielded encouraging 
results for discrimination between benign and malig-
nant disorders of the thyroid [11]. In the cited article, 
the authors found better rates of sensitivity, specificity, 
and PPV, even in cases with indeterminate FNA. They 
further concluded that detection of TSH mRNA might 
be beneficial in the postoperative follow-up of patients 
with thyroid malignancies. 
Levels of calcitonin are beneficial in the prediction 
and follow-up of patients with medullar thyroid carci-
noma [12], but similar correlation between differentia-
ted thyroid carcinomas and biochemical markers is still 
lacking. Thyroid carcinomas constitute a heterogeneous 
group of malignancy with ambiguous outcomes. There 
has been a demand for molecular markers to identify 
thyroid cancer pathogenesis and distinguish them from 
benign disorders of the thyroid [13]. Thyroglobulin has 
been extensively investigated from this aspect. Selective 
sampling has been the mainstay of some studies in cases 
with medullar thyroid cancers. 
It has been previously stated that selective venous 
sampling in patients with medullar thyroid carcinoma 
might be an effective tool in the detection of early 
recurrences [14]. In another study by Mohammed et 
al. [15], the role of calcitonin in 77 patients with med-
ullar thyroid cancers was studied by selective venous 
cannulation of the thyroid, cervical, and mediastinal 
regions. These two studies formed the basis of the idea 
of cannulating the inferior thyroid vein. 
Since the first demonstration by Van Herle et al. that 
thyroglobulin , the main iodo-protein of the thyroid 
gland, was detectable in the circulation of normal sub-
jects by using specific radioimmunoassay, an impres-
sive number of papers have been produced describing 
several clinical applications of Tg measurements, which 
is higher in some diseases such as follicular thyroid 
cancer [16].
Thyroglobulin (Tg) is a large molecule containing 
2,750 amino acids with a molecular weight of 330 kD 
and 20 putative N-linked glycosylation sites. Tg gene 
Table I. Mean values of thyroglobulin in blood taken from 
antecubital vein, inferior-superior thyroid veins, and their 
ratios relative to postoperative diagnosis according to 
permanent section
Tabela I. Średnie wartości stężenia tyreoglobuliny w próbkach 
krwi pobranych z żyły przedłokciowej i z żył tarczowych 
górnych i dolnych oraz stosunek tych wartości w zależności 
od pooperacyjnego rozpoznania histopatologicznego
  Thyroglobulin [ng/mL] p
Benign Malignant
ACV 9.94 ± 17.43 9.92 ± 16.34 0.33
ITV-STV 72.37 ± 34.98 68.4 ± 30.42 0.82
ACV/ITV-STV ratio 0.18 ± 0.29 0.31 ± 0.42 0.08
ACV — antecubital vein; ITV — inferior thyroid vein; STV — superior 
thyroid vein
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expression is regulated by thyroid transcription factor 1 
and human paired box 8. Iodinated Tg is stored in 
the lumen of the thyroid follicles and is released in 
response to specific hormonal stimulation by thyroid 
stimulating hormone (TSH). Following Tg reabsorption 
by thyrocytes and subsequent degradation, thyroid 
hormones triiodothryronine (T(3)) and thyroxine (T(4)) 
are secreted in the bloodstream [17].
Now, because of its higher levels in follicular cancer, 
the measurement of Tg is a mainstay of the post-surgical 
follow-up of follicular thyroid cancer, After total thyroid 
ablation by surgery and radioiodine, the Tg level should 
be measured. It must be undetectable, i.e. any detectable 
level should alert the clinician [18]. 
Ringel et al. [19] observed the importance of the 
levels of thyroglobulin in the early diagnosis of residual 
and recurrent thyroid carcinomas. They investigated 
the m-RNA of thyroglobulin by radioimmunoassay, and 
concluded that positive scans result in a dismal progno-
sis. Even if we have observed high levels of thyroglobulin 
in our patients with malignancy, these high levels did 
not correlate with the final diagnosis. This gives rise 
to the question as to whether, if we had used radioim-
munoassay, our results might have differed. Taking into 
account the high rates of thyroglobulin, both in benign 
and malign cases, it is disputable to make this kind of 
conclusion. Thorsen et al. [20] stated that preopera-
tive levels of thyroglobulin correlated with malignant 
disorders of the thyroid. According to our results, we 
do not agree with the statement that a significant cor-
relation can be achieved if the sampling has been made 
preoperatively. But high levels of thyroglobulin in benign 
diseases of our series are, to some degree, attributable to 
intraoperative over-manipulation of the thyroid gland or 
size of the nodule. There is also evidence to suggest that 
the difference in the levels of thyroglobulin in cases with 
a previous history of radiation exposure is significant in 
nodule formation [21]. 
Even if none of our patients was exposed to 
radiation, we agree that thyroglobulin levels might 
be altered by differential factors, beside the under-
lying disease. Bellantone et al. [22] have shown the 
presence of circulating thyroid follicle cells fol-
lowing thyroidectomy, by detecting thyroglobulin 
mRNA on rt-PCR (reverse transcriptase-Polymerase 
Chain Reaction) images. RT-PCR is capable of de-
tecting only one cancer cell in 105 cells. Using this 
kind of advanced method, together with selective 
venous sampling, might be helpful in identifying 
thyroid malignancies.
Conclusion
We believe that the progress towards identifying 
molecular markers that might be involved in thyroid 
cancer pathogenesis will be the pioneering scenario in 
the future treatment of thyroid disease.
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